Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
NPS Regains Global Rights To Gattex
by Rick Mullin
March 25, 2013
| A version of this story appeared in
Volume 91, Issue 12
NPS Pharmaceuticals has regained worldwide rights to recombinant human parathyroid hormone 1-84 and to Gattex, a therapy for patients with short bowel syndrome, from Japan’s Takeda Pharmaceutical. Takeda will receive NPS stock valued at $50 million and milestone payments over one year of up to $30 million. NPS had licensed rights to the compounds outside North America in 2004 and 2007, respectively, to Nycomed. Takeda acquired Nycomed in 2011.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter